Literature DB >> 16613992

Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase.

G Siriwardana1, A Bradford, D Coy, P Zeitler.   

Abstract

Although GHRH has previously been shown to regulate proliferation of breast cancer cells and prevent apoptosis, the intracellular pathways mediating this effect have not been clarified. Exogenous GHRH stimulated a dose-dependent proliferative response within 24 h in MDA-231, as well as in T47D cells and in MCF-7 cells transfected with the GHRH receptor. The proliferation of MDA-MB-231 (MDA-231) cells was associated with an increase in tritiated thymidine uptake. In addition, phosphorylation of MAPK was rapidly stimulated by GHRH. The phosphorylation of MAPK by GHRH was prevented by transfection of the cells with dominant-negative Ras or Raf or by pretreatment of cells with Raf kinase 1 inhibitor. The inhibition of Ras and Raf, as well as the inhibition of MAPK phosphorylation by PD98059, also prevented GHRH-induced cell proliferation. Finally, pretreatment of cells with the somatostatin analog, BIM23014, also prevented GHRH-induced MAPK phosphorylation and cell proliferation. These results indicate that GHRH stimulates dose-dependent cell proliferation of MDA-231 breast cancer cells through a pathway that requires Ras, Raf, and MAPK phosphorylation. The results also provide support for a possible autocrine/paracrine antagonism between GHRH and somatostatin in the regulation of MDA-231 cell population maintenance. Taken together, the studies provide further insight into the possible role of GHRH as a growth factor in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613992     DOI: 10.1210/me.2005-0001

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  16 in total

1.  Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.

Authors:  Ferenc G Rick; Andrew V Schally; Luca Szalontay; Norman L Block; Karoly Szepeshazi; Mehrdad Nadji; Marta Zarandi; Florian Hohla; Stefan Buchholz; Stephan Seitz
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-18       Impact factor: 11.205

2.  Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker.

Authors:  Un-Beom Kang; Younghee Ahn; Jong Won Lee; Yong-Hak Kim; Joon Kim; Myeong-Hee Yu; Dong-Young Noh; Cheolju Lee
Journal:  BMC Cancer       Date:  2010-03-26       Impact factor: 4.430

3.  Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.

Authors:  Hui Liu; Charles J Murphy; Florian A Karreth; Kristina B Emdal; Forest M White; Olivier Elemento; Alex Toker; Gerburg M Wulf; Lewis C Cantley
Journal:  Cancer Discov       Date:  2017-12-04       Impact factor: 39.397

4.  Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor.

Authors:  Nektarios Barabutis; Erasmia Tsellou; Andrew V Schally; Stavroula Kouloheri; Anastasios Kalofoutis; Hippokratis Kiaris
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

5.  Curcumin prevented human autocrine growth hormone (GH) signaling mediated NF-κB activation and miR-183-96-182 cluster stimulated epithelial mesenchymal transition in T47D breast cancer cells.

Authors:  Ajda Coker-Gurkan; Derya Bulut; Recep Genc; Elif-Damla Arisan; Pınar Obakan-Yerlikaya; Narcin Palavan-Unsal
Journal:  Mol Biol Rep       Date:  2018-11-23       Impact factor: 2.316

6.  Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer.

Authors:  Helena Pópulo; Bruno Nunes; Cristina Sampaio; Rui Batista; Marta Teixeira Pinto; Tiago B Gaspar; Leandro Miranda-Alves; Ren-Zhi Cai; Xian Yang Zhang; Andrew V Schally; Manuel Sobrinho-Simões; Paula Soares
Journal:  Horm Cancer       Date:  2017-09-18       Impact factor: 3.869

Review 7.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

8.  Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.

Authors:  Nektarios Barabutis; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

9.  Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation.

Authors:  Yong Jie Qin; Sun On Chan; Kelvin Kam Lung Chong; Benjamin Fuk Loi Li; Tsz Kin Ng; Yolanda Wong Ying Yip; Haoyu Chen; Mingzhi Zhang; Norman L Block; Herman S Cheung; Andrew V Schally; Chi Pui Pang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

10.  Activation of Janus kinase/signal transducer and activator of transcription 3 pathway by growth hormone-releasing hormone.

Authors:  Agnieszka Siejka; Andrew V Schally; Nektarios Barabutis
Journal:  Cell Mol Life Sci       Date:  2009-12-13       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.